Table 3.
Kidney myeloid immune cell populations by group
| Cell Type | Cell Gates | Control | Control + Saxagliptin | ANG II | Ang II +Saxagliptin |
|---|---|---|---|---|---|
| Neutrophils and natural killer cells | CD11b+ F4/80Lo Lineage+ Ly6C+ CD26+ | 7.29 ± 1.63 | 8.11 ± 1.75 | 19.56 ± 8.04¥ | 8.47 ± 2.89 |
| CD11b+ F4/80Lo macrophages | CD11b+ Lineage− CD11b+ F4/80Lo | 1.00 ± 0.00 | 1.03 ± 0.15 | 1.49 ± 0.37 | 1.65 ± 0.27§ |
| CD11b+ Lineage− CD11b+ F4/80Lo Ly6C− | 1.00 ± 0.00 | 0.94 ± 0.08 | 0.96 ± 0.06 | 0.88 ± 0.10 | |
| CD11b+ F4/80Lo Lineage− Ly6C− CD26+ | 1.00 ± 0.00 | 1.09 ± 0.08 | 1.19 ± 0.07* | 0.89 ± 0.09‡ | |
| CD11b+ Lineage− CD11b+ F4/80Lo Ly6C− CCR2+ | 1.00 ± 0.00 | 0.93 ± 0.16 | 0.99 ± 0.13 | 0.74 ± 0.05 | |
| CD11b+ Lineage− CD11b+ F4/80Lo Ly6CHi | 1.00 ± 0.00 | 1.05 ± 0.11 | 1.03 ± 0.06 | 1.12 ± 0.11 | |
| CD11b+ Lineage− CD11b+ F4/80Lo Ly6CHi CCR2+ | 1.00 ± 0.00 | 1.12 ± 0.12 | 1.05 ± 0.14 | 1.05 ± 0.16 | |
| CD11b+ Lineage− CD11b+ F4/80Lo Ly6CLo | 1.00 ± 0.00 | 1.19 ± 0.06 | 1.10 ± 0.13 | 1.20 ± 0.13 | |
| CD11b+ Lineage− CD11b+ F4/80Lo Ly6CLo CCR2+ | 1.00 ± 0.00 | 0.88 ± 0.06¥ | 1.04 ± 0.05 | 0.90 ± 0.01‡ | |
| CD11b+ F4/80− macrophages | CD11b+ F4/80− Lineage− | 1.00 ± 0.00 | 0.89 ± 0.14 | 0.92 ± 0.21 | 0.82 ± 0.08 |
| CD11b+ Lineage− CD11b+ F4/80− Ly6C− | 1.00 ± 0.00 | 0.92 ± 0.04 | 1.07 ± 0.07 | 0.84 ± 0.04*‡ | |
| CD11b+ Lineage− CD11b+ F4/80− Ly6CLo | 1.00 ± 0.00 | 1.27 ± 0.02 | 0.86 ± 0.14 | 1.22 ± 0.16‡ | |
| CD11b+ Lineage− CD11b+ F4/80− Ly6CHi | 1.00 ± 0.00 | 0.95 ± 0.12 | 0.93 ± 0.16 | 1.21 ± 0.19 | |
| CD11b+ Lineage− CD11b+ F4/80− CD26Hi | 1.00 ± 0.00 | 1.28 ± 0.10* | 1.32 ± 0.02* | 1.06 ± 0.11‡ | |
| CD11b+ Lineage− CD11b+ F4/80− CD26Lo | 1.00 ± 0.00 | 1.14 ± 0.17 | 1.52 ± 0.22* | 1.39 ± 0.19 | |
| Dendritic cells | CD11bNeg-Lo F4/80Hi Lineage− | 1.00 ± 0.00 | 1.19 ± 0.10 | 1.08 ± 0.07 | 1.03 ± 0.06 |
| CD11bNeg-Lo F4/80Hi Lineage− CCR2− | 90.62 ± 4.48 | 88.85 ± 5.54 | 92.20 ± 3.11 | 90.68 ± 4.38 | |
| CD11bNeg-Lo F4/80Hi Lineage− CX3CR1+ | 99.88 ± 0.08 | 99.95 ± 0.03 | 99.70 ± 0.15 | 99.60 ± 0.22 | |
| CD11bNeg-Lo F4/80Hi Lineage− CX3CR1+ CD11c+ | 96.53 ± 0.36 | 95.72 ± 0.62 | 95.15 ± 0.54 | 95.67 ± 0.70 | |
| CD11bNeg-Lo F4/80Hi Lineage− CX3CR1+ CD11c− | 1.00 ± 0.00 | 1.27 ± 0.18 | 1.50 ± 0.22 | 1.24 ± 0.15 | |
| Natural killer cells | B&NK Cells/CX3CR1Hi | 1.00 ± 0.00 | 0.96 ± 0.19 | 0.70 ± 0.10¥ | 0.66 ± 0.04¥ |
| B&NK Cells/CX3CR1Lo Ly6C− | 78.62 ± 2.97 | 78.80 ± 2.34 | 81.95 ± 1.43 | 80.88 ± 2.12 | |
| B&NK Cells/CX3CR1Lo Ly6CHi | 9.01 ± 0.68 | 11.06 ± 1.44 | 8.75 ± 1.02 | 7.47 ± 0.41 | |
| B&NK Cells/CX3CR1Lo Ly6CLo | 10.40 ± 1.35 | 10.14 ± 1.22 | 9.32 ± 0.95 | 8.92 ± 0.62 | |
| Neutrophils | CD45+ T-B-NK1.1−Ly6G+ | 5.43 ± 0.28 | 6.23 ± 0.45 | 8.81 ± 1.37* | 5.76 ± 0.47‡ |
Values are means ± SE (absolute or relative to control); n = 4–6 mice per group. Statistical significance was determined using two-way ANOVA followed by Fisher’s LSD post hoc analysis. *P < 0.05 vs. control; ‡P < 0.05 vs. ANG II; ¥P = 0.05–0.09 vs. control; §P = 0.07 vs. ANG II. ANG II, angiotensin II.